GlassScriptPhysician profile
Sabrina Cordero
NPI 1578929022
$6,377.51
in general payments reported to CMS, 2019-2025
32 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.19 · 2022: $826 · 2023: $1,449 · 2024: $1,766 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,301 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,300.84 |
| Education | $236.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $847.84 | 2022-2025 | Enhertu, Injectafer |
| Incyte Corporation | $672.81 | 2022-2025 | Jakafi, Jakafi, Zynyz |
| Novartis Pharmaceuticals Corporation | $531.59 | 2022-2025 | |
| Sobi, INC | $531.37 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $527.96 | 2023-2025 | Monoferric |
| Genzyme Corporation | $476.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $345.77 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Rigel Pharmaceuticals, INC. | $338.51 | 2022-2023 | Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $318.67 | 2023-2025 | Enhertu |
| Pharmaessentia USA Corporation | $218.38 | 2024-2025 | Besremi |
| Lilly USA, LLC | $168.70 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $158.90 | 2022-2024 | Vonvendi, Fruzaqla, Ninlaro |
| Agios Pharmaceuticals, INC. | $141.90 | 2022-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $138.53 | 2023-2025 | |
| Eisai INC. | $106.90 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $102.84 | 2024-2025 | Sylvant |
| Apellis Pharmaceuticals, INC. | $93.98 | 2022-2025 | Empaveli |
| Taiho Oncology, INC. | $82.73 | 2024-2025 | |
| Astellas Pharma US INC | $69.99 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $61.93 | 2024-2025 | Onivyde, Somatuline Depot |
| Pfizer INC. | $61.59 | 2023-2024 | |
| Blueprint Medicines Corporation | $57.25 | 2025 | Ayvakit |
| Janssen Pharmaceuticals, INC | $55.63 | 2024 | Xarelto |
| Springworks Therapeutics, INC. | $55.09 | 2025 | Ogsiveo |
| Alnylam Pharmaceuticals INC. | $42.92 | 2022-2024 | Givlaari |
| Global Blood Therapeutics, INC. | $36.78 | 2022 | |
| Jazz Pharmaceuticals INC. | $27.72 | 2025 | |
| Geron Corporation | $25.38 | 2025 | Rytelo |
| Kedrion Biopharma, INC. | $22.61 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Adaptive Biotechnologies Corporation | $22.23 | 2023 | Clonoseq |
| Csl Behring | $20.21 | 2023 | Idelvion |
| Dova Pharmaceuticals | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Cordero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.